Mirvetuximab Soravtansine Combo Therapies Show Promise for Ovarian Cancer, Clinical Trial Shows

Mirvetuximab Soravtansine Combo Therapies Show Promise for Ovarian Cancer, Clinical Trial Shows
Combinations of mirvetuximab soravtansine (IMGN853) with either Avastin (bevacizumab) or Paraplatin (carboplatin) are showing promise in certain ovarian cancer patients, particularly those who received multiple prior lines of therapy, the investigational therapy’s developer, ImmunoGen, recently announced. The data come from an ongoing Phase 1b/2 trial. Mirvetuximab soravtansine is a potential new treatment for patients with folate receptor alpha (FRα)-positive cancer. It

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *